A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but…

WSJ News Exclusive | The New Green Investment: Getting Clean Energy to Big Cities

U.S. cities racing to cut their emissions are facing a roadblock: They can’t access the wind…

Can a Big Pharma Ever Be Worth $1 Trillion?

There are five tech companies valued at over $1 trillion. In healthcare, the closest contender is…

Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity

Novo Nordisk, the Danish pharmaceutical giant that makes the blockbuster Wegovy obesity drug, said it will…

Obesity Drug Demand Outstrips Supply

Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as…

Never Mind Covid, Investors Want a Pfizer Obesity Pill

Some of this year’s best performers in the healthcare sector are companies expected to profit from…

Ozempic Maker Novo Nordisk Has a Weight Problem

Oct. 23, 2023 11:39 am ET The company behind diabetes and obesity phenomena Ozempic and Wegovy…

Stocks Clinch Four-Day Winning Streak

Long-term Treasury yields continued to ease.

Amgen Could Get a Piece of the Obesity Market

Amgen has a couple of shots on goal to break into one of the biggest markets…

To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit-Card Debts

Some people are paying more than $10,000 a year for Ozempic and Mounjaro.